PE20130243A1 - Combinacion farmaceutica - Google Patents

Combinacion farmaceutica

Info

Publication number
PE20130243A1
PE20130243A1 PE2012002241A PE2012002241A PE20130243A1 PE 20130243 A1 PE20130243 A1 PE 20130243A1 PE 2012002241 A PE2012002241 A PE 2012002241A PE 2012002241 A PE2012002241 A PE 2012002241A PE 20130243 A1 PE20130243 A1 PE 20130243A1
Authority
PE
Peru
Prior art keywords
methyl
dimethylamino
phenol
propyl
ethyl
Prior art date
Application number
PE2012002241A
Other languages
English (en)
Inventor
Klaus Schiene
Petra Blomsfunke
Original Assignee
Gruenenthal Chemie
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42395008&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20130243(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Gruenenthal Chemie filed Critical Gruenenthal Chemie
Publication of PE20130243A1 publication Critical patent/PE20130243A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

SE REFIERE A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE: A) EL COMPUESTO 3-(3-DIMETILAMINO-1-ETIL-2-METIL-PROPIL)-FENOL EN FORMA DE UNO DE SUS ESTEREOISOMEROS TALES COMO (1R,2R)-3-(3-DIMETILAMINO-1-ETIL-2-METIL-PROPIL)-FENOL, (1S,2S)-3-(3-DIMETILAMINO-1-ETIL-2-METIL-PROPIL)-FENOL, (1R,2S)-3-(3-DIMETILAMINO-1-ETIL-2-METIL-PROPIL)-FENOL, ENTRE OTROS; Y B) UN ANTAGONISTA DEL RECEPTOR N-METIL-D-ASPARTATO (NMDA) TAL COMO (R,S)-QUETAMINA, (S)-QUETAMINA, MEMANTINA, NORVALINA, ENTRE OTROS. DICHA COMPOSICION FARMACEUTICA ES UTIL EN EL TRATAMIENTO DEL DOLOR Y PRESENTA UN EFECTO SINERGICO
PE2012002241A 2010-06-15 2011-06-14 Combinacion farmaceutica PE20130243A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP10006202 2010-06-15

Publications (1)

Publication Number Publication Date
PE20130243A1 true PE20130243A1 (es) 2013-03-22

Family

ID=42395008

Family Applications (2)

Application Number Title Priority Date Filing Date
PE2012002241A PE20130243A1 (es) 2010-06-15 2011-06-14 Combinacion farmaceutica
PE2016000337A PE20160531A1 (es) 2010-06-15 2011-06-14 Combinacion farmaceutica

Family Applications After (1)

Application Number Title Priority Date Filing Date
PE2016000337A PE20160531A1 (es) 2010-06-15 2011-06-14 Combinacion farmaceutica

Country Status (29)

Country Link
US (3) US8846765B2 (es)
EP (2) EP2992877A1 (es)
JP (3) JP6133772B2 (es)
KR (1) KR101831616B1 (es)
CN (1) CN103108631B (es)
AR (1) AR081931A1 (es)
AU (2) AU2011267474B2 (es)
BR (1) BR112012031836A2 (es)
CA (1) CA2796774C (es)
CL (1) CL2012002551A1 (es)
CO (1) CO6602157A2 (es)
CY (1) CY1117118T1 (es)
DK (1) DK2582366T3 (es)
EC (2) ECSP12012217A (es)
ES (1) ES2560676T3 (es)
HK (2) HK1215787A1 (es)
HR (1) HRP20151327T1 (es)
HU (1) HUE026619T2 (es)
IL (1) IL221926A (es)
MX (1) MX2012014482A (es)
NZ (1) NZ602625A (es)
PE (2) PE20130243A1 (es)
PL (1) PL2582366T3 (es)
PT (1) PT2582366E (es)
RS (1) RS54439B1 (es)
RU (2) RU2589692C2 (es)
SI (1) SI2582366T1 (es)
WO (1) WO2011157391A1 (es)
ZA (1) ZA201208646B (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8846765B2 (en) * 2010-06-15 2014-09-30 Gruenenthal Gmbh Pharmaceutical combination
US9737531B2 (en) 2012-07-12 2017-08-22 Glytech, Llc Composition and method for treatment of depression and psychosis in humans
MX2014010939A (es) * 2012-03-12 2014-11-13 Janssen Pharmaceutica Nv Esketamina para el tratamiento de la depresion refractaria al tratamiento o resistente al tratamiento.
DK2948140T3 (en) * 2013-01-22 2017-08-21 Vistagen Therapeutics Inc DOSAGE FORMS AND THERAPEUTIC APPLICATIONS OF L-4-CHLORCYNURENINE
AU2014240102A1 (en) 2013-03-15 2015-09-17 Janssen Pharmaceutica Nv Pharmaceutical composition of S-ketamine hydrochloride
CN103655523A (zh) * 2013-12-24 2014-03-26 南京艾德凯腾生物医药有限责任公司 他喷他多组合物
WO2015171770A1 (en) * 2014-05-06 2015-11-12 Northwestern University Combinations of nmdar modulating compounds
WO2016025581A1 (en) 2014-08-13 2016-02-18 Janssen Pharmaceutica Nv Method for the treatment of depression
US20160074340A1 (en) 2014-09-15 2016-03-17 Janssen Pharmaceutica Nv VAL66MET (SNP rs6265) GENOTYPE SPECIFIC DOSING REGIMENS AND METHODS FOR THE TREATMENT OF DEPRESSION
US20160332962A1 (en) 2015-05-13 2016-11-17 Janssen Pharmaceutica Nv (s)-csa salt of s-ketamine, (r)-csa salt of s-ketamine and processes for the preparation of s-ketamine
US11191734B2 (en) 2015-06-27 2021-12-07 Shenox Pharmaceuticals, Llc Ketamine transdermal delivery system
US20200009081A1 (en) 2017-09-13 2020-01-09 Janssen Pharmaceutica N.V. Delivery Of Esketamine For The Treatment Of Depression
CN117531017A (zh) 2017-12-22 2024-02-09 詹森药业有限公司 用于治疗抑郁症的艾司氯胺酮
CN112105349A (zh) * 2018-04-12 2020-12-18 阿纳韦克斯生命科学公司 A2-73结晶多晶型物质组合物及其使用方法
WO2020178653A1 (en) 2019-03-05 2020-09-10 Janssen Pharmaceuticals, Inc. Esketamine for the treatment of depression

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3391142A (en) 1966-02-09 1968-07-02 Lilly Co Eli Adamantyl secondary amines
US4389393A (en) 1982-03-26 1983-06-21 Forest Laboratories, Inc. Sustained release therapeutic compositions based on high molecular weight hydroxypropylmethylcellulose
US4612008A (en) 1983-05-11 1986-09-16 Alza Corporation Osmotic device with dual thermodynamic activity
US4783337A (en) 1983-05-11 1988-11-08 Alza Corporation Osmotic system comprising plurality of members for dispensing drug
US4765989A (en) 1983-05-11 1988-08-23 Alza Corporation Osmotic device for administering certain drugs
US5472711A (en) 1992-07-30 1995-12-05 Edward Mendell Co., Inc. Agglomerated hydrophilic complexes with multi-phasic release characteristics
US5330761A (en) 1993-01-29 1994-07-19 Edward Mendell Co. Inc. Bioadhesive tablet for non-systemic use products
US5455046A (en) 1993-09-09 1995-10-03 Edward Mendell Co., Inc. Sustained release heterodisperse hydrogel systems for insoluble drugs
US5399362A (en) 1994-04-25 1995-03-21 Edward Mendell Co., Inc. Once-a-day metoprolol oral dosage form
DE4426245A1 (de) * 1994-07-23 1996-02-22 Gruenenthal Gmbh 1-Phenyl-3-dimethylamino-propanverbindungen mit pharmakologischer Wirkung
US6248789B1 (en) * 1996-08-29 2001-06-19 Stuart L. Weg Administration of ketamine to manage pain and to reduce drug dependency
US6007841A (en) * 1998-03-13 1999-12-28 Algos Pharmaceutical Corporation Analgesic composition and method for treating pain
DE69933874T2 (de) * 1998-07-16 2007-10-04 Memorial Sloan-Kettering Institute For Cancer Research Topische zusammensetzung enthaltend ein opioid-analgetika und einen nmda-antagonist
DE10005302A1 (de) * 2000-02-07 2002-01-17 Gruenenthal Gmbh Substituierte 1,2,3,4-Tetrahydrochinolin-2-carbonsäurederivate
US20010036943A1 (en) 2000-04-07 2001-11-01 Coe Jotham W. Pharmaceutical composition for treatment of acute, chronic pain and/or neuropathic pain and migraines
PE20030527A1 (es) * 2001-10-24 2003-07-26 Gruenenthal Chemie Formulacion farmaceutica con liberacion retardada que contiene 3-(3-dimetilamino-1-etil-2-metil-propil) fenol o una sal farmaceuticamente aceptable del mismo y tabletas para administracion oral que la contienen
DE10163421A1 (de) 2001-12-21 2003-07-31 Gruenenthal Gmbh Verwendung von (+)-(1S,2S)-3-(3-Dimethylamino-1-ethyl-2-methyl-propyl)phenol als Antiemetikum
JP2003201254A (ja) * 2001-12-28 2003-07-18 Hisamitsu Pharmaceut Co Inc 鎮痛剤活性増強剤の治療上有効な血中濃度を維持するための製剤
JP2003210254A (ja) * 2002-01-18 2003-07-29 Nihon Form Service Co Ltd 車椅子専用ラック
EP1545461A4 (en) 2002-09-09 2011-06-22 Endo Pharmaceuticals Inc COMBINED ANALGESIC COMPOSITION WITH IMMEDIATE AND PROLONGED RELEASE
US7273889B2 (en) * 2002-09-25 2007-09-25 Innovative Drug Delivery Systems, Inc. NMDA receptor antagonist formulation with reduced neurotoxicity
WO2007087452A2 (en) * 2006-01-27 2007-08-02 Theraquest Biosciences, Llc Abuse resistant and extended release formulations and method of use thereof
US20070254960A1 (en) 2006-04-28 2007-11-01 Gruenenthal Gmbh Pharmaceutical combination
DK2012763T3 (da) 2006-04-28 2011-05-02 Gruenenthal Gmbh Farmaceutisk kombination omfattende 3-(3-dimethylamono-1-ethyl-2-methyl-propyl) phenol og et NSAID
RU2442576C2 (ru) 2006-04-28 2012-02-20 Грюненталь Гмбх Фармацевтическая комбинация, содержащая 3-(3-диметиламино-1-этил-2-метилпропил)фенол и парацетамол
EP1857463A1 (en) 2006-05-03 2007-11-21 Ebewe Pharma Ges.m.b.H. Nfg. KG Peptide having neuroprotective effects
CA2652667A1 (en) 2006-06-08 2007-12-13 Schwarz Pharma Ag Therapeutic combination for painful medical conditions
SA07280459B1 (ar) 2006-08-25 2011-07-20 بيورديو فارما إل. بي. أشكال جرعة صيدلانية للتناول عن طريق الفم مقاومة للعبث تشتمل على مسكن شبه أفيوني
DE102007012165A1 (de) * 2007-03-12 2008-09-18 Grünenthal GmbH Verwendung von 1-Phenyl-3-dimethylamino-propanverbindungen zur Therapie des Neuropathieschmerzes
CN102065852B (zh) * 2007-11-23 2015-06-17 格吕伦塔尔有限公司 他喷他多组合物
US8383152B2 (en) 2008-01-25 2013-02-26 Gruenenthal Gmbh Pharmaceutical dosage form
WO2009094563A2 (en) * 2008-01-25 2009-07-30 Xenoport, Inc. Crystalline form of calcium-salts of (3s)-aminomethyl-b-methyl-hexanoic acids and methods of use
US20100190752A1 (en) 2008-09-05 2010-07-29 Gruenenthal Gmbh Pharmaceutical Combination
MX2011002339A (es) * 2008-09-05 2011-04-04 Gruenenthal Gmbh Combinacion farmaceutica de 3-(3-dimetilamino-1-etil-2-metil-propi l)-fenol y un antiepileptico.
US8846765B2 (en) * 2010-06-15 2014-09-30 Gruenenthal Gmbh Pharmaceutical combination
JP5977240B2 (ja) 2010-09-21 2016-08-24 パーデュー、ファーマ、リミテッド、パートナーシップ ブプレノルフィン類似体
EA032906B1 (ru) 2010-12-22 2019-08-30 Пэдью Фарма Л.П. Твердая лекарственная форма с контролируемым высвобождением и способы ее получения и применения
RS54711B1 (en) 2011-03-04 2016-08-31 Grünenthal GmbH PARENTERAL TAPENTADOL ADMINISTRATION
AR092820A1 (es) 2012-04-17 2015-05-06 Purdue Pharma Lp Sistemas y metodos para tratar una respuesta farmacodinamica adversa inducida por opioides, unidad de dosis, kit

Also Published As

Publication number Publication date
RU2016119041A (ru) 2017-11-20
MX2012014482A (es) 2013-02-21
CA2796774A1 (en) 2011-12-22
RS54439B1 (en) 2016-06-30
US8846765B2 (en) 2014-09-30
KR101831616B1 (ko) 2018-04-04
JP6197007B2 (ja) 2017-09-13
CN103108631B (zh) 2015-08-26
EP2582366B1 (en) 2015-10-28
CO6602157A2 (es) 2013-01-18
SI2582366T1 (sl) 2016-02-29
ES2560676T3 (es) 2016-02-22
EP2582366A1 (en) 2013-04-24
HRP20151327T1 (hr) 2016-01-01
CL2012002551A1 (es) 2012-11-09
HK1184370A1 (zh) 2014-01-24
AU2011267474A1 (en) 2013-01-10
JP6423036B2 (ja) 2018-11-14
AU2011267474B2 (en) 2016-05-26
US20140309311A1 (en) 2014-10-16
ECSP19047259A (es) 2019-07-31
US20110306674A1 (en) 2011-12-15
JP2015232015A (ja) 2015-12-24
PE20160531A1 (es) 2016-06-05
US10813890B2 (en) 2020-10-27
KR20130111945A (ko) 2013-10-11
CY1117118T1 (el) 2017-04-05
CN103108631A (zh) 2013-05-15
AU2016219643A1 (en) 2016-09-15
BR112012031836A2 (pt) 2016-11-08
ECSP12012217A (es) 2012-11-30
RU2013101515A (ru) 2014-07-20
NZ602625A (en) 2014-03-28
IL221926A (en) 2015-08-31
PL2582366T3 (pl) 2016-04-29
ZA201208646B (en) 2013-09-25
RU2675261C2 (ru) 2018-12-18
AR081931A1 (es) 2012-10-31
WO2011157391A1 (en) 2011-12-22
US20170333369A1 (en) 2017-11-23
JP2017141277A (ja) 2017-08-17
AU2016219643B2 (en) 2018-04-12
EP2992877A1 (en) 2016-03-09
JP6133772B2 (ja) 2017-05-24
PT2582366E (pt) 2016-01-26
CA2796774C (en) 2020-06-02
DK2582366T3 (en) 2015-12-07
HK1215787A1 (zh) 2016-09-15
RU2589692C2 (ru) 2016-07-10
JP2013528629A (ja) 2013-07-11
HUE026619T2 (en) 2016-06-28

Similar Documents

Publication Publication Date Title
PE20130243A1 (es) Combinacion farmaceutica
PE20142372A1 (es) Combinacion farmaceutica de 3-(3-dimetilamino-1-etil-2-metil-propil)-fenol y un antiepileptico
ECSP13012368A (es) Composiciones farmacéuticas de co-cristales de tramadol y coxibs
EA201290982A1 (ru) Фармацевтические композиции, препятствующие злоупотреблению
CL2014000956A1 (es) Compuestos derivados de (4-fenilimidazol-2-il)etilamina, como moduladores de canal de sodio; composicion farmaceutica que los comprende; y su uso en el tratamiento del dolor.
AR089931A1 (es) Composiciones farmaceuticas que contienen dimetilfumarato
UY31863A (es) Combinaciones de drogas que comprenden un inhibidor de dgat y un agonista de ppar
CL2015000121A1 (es) El compuesto 1-(1-metil-1h-pirazol-4-il)-n-((1r,5s,7s)-9-metil-3-oxa-9-azabiciclo[3.3.1]-nonan-7-il)-1h-indol-3-carboxamida, antagonista del receptor de 5-ht3; composicion farmaceutica; y su uso como medicamento
CO6400170A2 (es) Agosnistas y antagonistas del receptor s1p5 y métodos de uso de los mismos
DOP2011000249A (es) Compuesto de anillo fusionado y su uso
NI201000053A (es) Trans-clomifeno para el síndrome metabólico.
CL2015002462A1 (es) Polímero conjugado para entregar un agente bioactivo
CL2012003521A1 (es) Derivado piperidino (r)-n-((r)-1-((3s-4s)-4-(4-clorofenil)-3,4-dihidroxi-3-metilpiperidin-1-il)-3-metil-1-oxobutan-2-il)-3,3-difluorociclopentanocarboxamida, modulador receptor quimiocinas; composicion farmaceutica; y uso del compuesto y su composicion en enfermedades inflamatorias y autoinmunitarias, entre otras.
EA201591830A1 (ru) Фармацевтические композиции, включающие эверолимус
UY32734A (es) Compuestos agonistas del receptor esfingosina 1-fosfato
GB2523707A (en) Novel pharmaceutical formulations and their use in the treatment of periodontal disease
EA201590932A1 (ru) Композиции, содержащие вортиоксетин и донепезил
CL2012000097A1 (es) Compuestos derivados de 3-fenoximetilpirrolidina, inhibidores de la recaptacion de serotonina-norepinefrina; procedimiento de preparacion; compuestos intermediarios; composicion farmaceutica que lo comprende; y su uso en el tratamiento de trastornos del dolor, depresion, entre otros.
CO6592109A2 (es) Nueva forma cristalina de un derivado de ciclopropilbenzamida
PE20151300A1 (es) Composicion antifungica topica para el tratamiento de onicomicosis
GT200900296A (es) Composición farmacéutica que comprende la combinación de un agente anti inflamatorio no esteroideo y un agente anticonvulsivante.
GEP20186908B (en) P-substituted asymmetric ureas and medical uses thereof
PE20130813A1 (es) Nueva asociacion entre la 4-{3-[cis-hexahidrociclopenta[c]pirrol-2(1h)-il]propoxi}benzamida y un antagonista de los receptores nmda y las composiciones farmaceuticas que la contienen
CO2017001076A2 (es) Composiciones farmacéuticas antihiperalgésicas, antialodínicas y antiinflamatorias que contienen pregabalina y meloxicam
DOP2015000127A (es) Formulación farmacéutica de n-[5-[2-(3,5-dimetoxifenil)etil]-2h-pirazol-3-il]-4-[(3r,5s)-3,5-dimetilpiperazin-1-il] benzamida

Legal Events

Date Code Title Description
FG Grant, registration